Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
福爾摩沙製藥與薩瓦爾公司宣佈關於克雷莫特脲眼用懸液的許可協議,用於治療手術後的炎症和疼痛
Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
福爾摩沙製藥與薩瓦爾公司宣佈關於克雷莫特脲眼用懸液的許可協議,用於治療手術後的炎症和疼痛
使用瀏覽器的分享功能,分享給你的好友吧
- 没有更多了 -